Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance

Journal of Medicinal Chemistry

Volumn 52, Issue 19, 2009, Pages 5789-5792

  De Carvalho, Luiz Pedro S ^a   Lin, Gang ^a   Jiang, Xiuju ^a   Nathan, Carl ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITAZOXANIDE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANTIPARASITIC AGENTS; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; THIAZOLES;

EID: 70349647606     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9010719     Document Type: Article

References (32)

1. Gandhi, N. R.; Moll, A.; Sturm, A. W.; Pawinski, R.; Govender, T.; Lalloo, U.; Zeller, K.; Andrews, J.; Friedland, G. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368, 1575-1580. (Pubitemid 44780738)
2. Raviglione, M. C.; Smith, I. M. XDR tuberculosis - implications for global public health. N. Engl. J. Med. 2007, 356, 656-659. (Pubitemid 46257227)
3. Canetti, G. Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. 1965, 92, 687-703.
4. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H. W.; Neefs, J. M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307, 223-227. (Pubitemid 40116230)
5. Hillemann, D.; Rusch-Gerdes, S.; Richter, E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob. Agents Chemother. 2008, 52, 800-801. (Pubitemid 351170872)
6. Manjunatha, U. H.; Boshoff, H.; Dowd, C. S.; Zhang, L.; Albert, T. J.; Norton, J. E.; Daniels, L.; Dick, T.; Pang, S. S.; Barry, C. E., 3rd. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 431-436.
7. Nathan, C. Antibiotics at the crossroads. Nature 2004, 431, 899-902.
8. Nathan, C.; Gold, B.; Lin, G.; Stegman, M.; de Carvalho, L. P.; Vandal, O.; Venugopal, A.; Bryk, R. A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis (Edinburgh) 2008, 88 (Suppl. 1), S25-S33.
9. Bryk, R.; Gold, B.; Venugopal, A.; Singh, J.; Samy, R.; Pupek, K.; Cao, H.; Popescu, C.; Gurney, M.; Hotha, S.; Cherian, J.; Rhee, K.; Ly, L.; Converse, P. J.; Ehrt, S.; Vandal, O.; Jiang, X.; Schneider, J.; Lin, G.; Nathan, C. Selective killing of nonreplicating mycobacteria. Cell Host Microbe 2008, 3, 137-145.
10. Adagu, I. S.; Nolder, D.; Warhurst, D. C.; Rossignol, J. F. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. 2002, 49, 103-111. (Pubitemid 34100652)
11. Rossignol, J. F. Parasitic gut infections. Curr. Opin. Infect. Dis. 1998, 11, 597-600.
12. Rossignol, J. F.; Kabil, S. M.; El-Gohary, Y.; Elfert, A.; Keeffe, E. B. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther. 2008, 28, 574-580.
13. Megraud, F.; Occhialini, A.; Rossignol, J. F. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob. Agents Chemother. 1998, 42, 2836-2840. (Pubitemid 28501212)
14. Musher, D. M.; Logan, N.; Hamill, R. J.; Dupont, H. L.; Lentnek, A.; Gupta, A.; Rossignol, J. F. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 2006, 43, 421-427. (Pubitemid 44157148)
15. Keeffe, E. B.; Rossignol, J. F. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J. Gastroenterol. 2009, 15, 1805-1808.
16. Theodos, C. M.; Griffiths, J. K.; D'Onfro, J.; Fairfield, A.; Tzipori, S. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models. Antimicrob. Agents Chemother. 1998, 42, 1959-1965. (Pubitemid 28363076)
17. Hoffman, P. S.; Sisson, G.; Croxen, M. A.; Welch, K.; Harman, W. D.; Cremades, N.; Morash, M. G. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 2007, 51, 868-876.
18. Sisson, G.; Goodwin, A.; Raudonikiene, A.; Hughes, N. J.; Mukhopadhyay, A. K.; Berg, D. E.; Hoffman, P. S. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 2002, 46, 2116-2123.
19. Muller, J.; Wastling, J.; Sanderson, S.; Muller, N.; Hemphill, A. A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob. Agents Chemother. 2007, 51, 1979-1986. (Pubitemid 46903083)
20. Muller, J.; Naguleswaran, A.; Muller, N.; Hemphill, A. Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. Exp. Parasitol. 2008, 118, 80-88. (Pubitemid 350299339)
21. Dubreuil, L.; Houcke, I.; Mouton, Y.; Rossignol, J. F. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 1996, 40, 2266-2270.
22. Physicians' Desk Reference 2009, 63rd ed.; Thomson Reuters: Montvale, NJ, 2008; pp 2677-2678.
23. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405, 962-966. (Pubitemid 30435054)
24. Sander, P.; Belova, L.; Kidan, Y. G.; Pfister, P.; Mankin, A. S.; Bottger, E. C. Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations. Mol. Microbiol. 2002, 46, 1295-1304.
25. Teo, J. W.; Thayalan, P.; Beer, D.; Yap, A. S.; Nanjundappa, M.; Ngew, X.; Duraiswamy, J.; Liung, S.; Dartois, V.; Schreiber, M.; Hasan, S.; Cynamon, M.; Ryder, N. S.; Yang, X.; Weidmann, B.; Bracken, K.; Dick, T.; Mukherjee, K. Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother. 2006, 50, 3665-3673. (Pubitemid 44684879)
26. Billington, O. J.; McHugh, T. D.; Gillespie, S. H. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1999, 43, 1866-1869.
27. Aly, S.; Wagner, K.; Keller, C.; Malm, S.; Malzan, A.; Brandau, S.; Bange, F. C.; Ehlers, S. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 2006, 210, 298-305. (Pubitemid 44660508)
28. Via, L. E.; Lin, P. L.; Ray, S. M.; Carrillo, J.; Allen, S. S.; Eum, S. Y.; Taylor, K.; Klein, E.; Manjunatha, U.; Gonzales, J.; Lee, E. G.; Park, S. K.; Raleigh, J. A.; Cho, S. N.; McMurray, D. N.; Flynn, J. L.; Barry, C. E., 3rd. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 2008, 76, 2333-2340.
29. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358, 591-593.
30. Singh, R.; Manjunatha, U.; Boshoff, H. I.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., 3rd. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008, 322, 1392-1395.
31. Silver, L. L. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discovery 2007, 6, 41-55.
32. Singh, B.; Mitchison, D. A. Bactericidal activity of streptomycin and isoniazid against tubercle bacilli. Br. Med. J. 1954, 1, 130-132.